Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system

References

• McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142–8
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm 2013;39:39–50
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:103–7
   PubMed Web of Science ®Google Scholar
• Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol Med Sci 1955;33:415–19
   PubMedGoogle Scholar
• Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987–91
   PubMed Web of Science ®Google Scholar
• Swanson DR, Barclay BL, Wong PS, Theeuwes F. Nifedipine gastrointestinal therapeutic system. Am J Med 1987;83:3–9
   PubMedGoogle Scholar
• Tang X, Tai L, Yang X, et al. In vitro and in vivo evaluation of gliclazide push–pull osmotic pump coated with aqueous colloidal polymer dispersions. Drug Dev Ind Pharm 2013;39:67–76
   PubMed Web of Science ®Google Scholar
• Liu L, Ku J, Khang G, et al. Nifedipine controlled delivery by sandwiched osmotic tablet system. J Control Release 2000;68:145–56
   PubMed Web of Science ®Google Scholar
• Shokri J, Ahmadi P, Rashidi P, et al. Swellable elementary osmotic pump (SEOP): An effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm 2008;68:289–97
   PubMed Web of Science ®Google Scholar
• Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res 1998;15:889–96
   PubMed Web of Science ®Google Scholar
• Malaterre V, Ogorka J, Loggia N, Gurny R. Approach to design push-pull osmotic pumps. Int J Pharm 2009;376:56–62
   PubMed Web of Science ®Google Scholar
• Verma RK, Garg S. Development and evaluation of osmotic controlled oral drug delivery system of glipzide. Eur J Pharm Biopharm 2004;57:513–25
   PubMed Web of Science ®Google Scholar
• Liu LX, Wang XC. Solubility-modulated monolithic osmotic pump tablet for atenolol delivery. Eur J Pharm Biopharm 2008;68:298–302
   PubMed Web of Science ®Google Scholar
• Okimoto K, Tokunaga Y, Ibuki R, et al. Applicability of (SBE)7m-β-CD in controlled-porosity osmotic pump tablets (OPTs). Int J Pharm 2004;286:81–8
   PubMed Web of Science ®Google Scholar
• Özdemir N, Sahin J. Design of a controlled release osmotic pump system of ibuprofen. Int J Pharm 1997;158:91–7
   Web of Science ®Google Scholar
• Grattoni A, Merlo M, Ferrari M. Osmotic pressure beyond concentration restrictions. J Phys Chem B 2007;111:11770–5
   PubMed Web of Science ®Google Scholar
• Guo JH. Effects of plasticizers on water permeation and mechanical properties of cellulose-acetate-antiplasticization in slightly plasticized polymer film. Drug Dev Ind Pharm 1993;19:1541–55
   Web of Science ®Google Scholar
• Rani M, Mishra B. Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS PharmSciTech 2004;5:153–9
   Web of Science ®Google Scholar
• Bindschaedler C, Gurny R, Doelker E. Osmotic water transport through cellulose acetate membranes produced from a latex system. J Pharm Sci 1987;76:455–60
   PubMed Web of Science ®Google Scholar
• Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine I. Cellulose acetate as a semipermeable membrane. J Control Release 2003;89:5–18
   PubMed Web of Science ®Google Scholar
• Ofori-Kwakye K, Fell JT. Biphasic drug release from film-coated tablets. Int J Pharm 2003;250:431–40
   PubMed Web of Science ®Google Scholar
• Takano A, Suhara T, Kusumi I, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:75–81
   PubMed Web of Science ®Google Scholar
• Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in firstepisode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992–7
   PubMed Web of Science ®Google Scholar
• Chue P, Llorca PM, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005;5:266–74
   Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250–7
   PubMed Web of Science ®Google Scholar
• Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986;3:123–31
   PubMed Web of Science ®Google Scholar